Analyst firms · Oppenheimer · ASND

Oppenheimer ASND price target and rating history

Ascendis Pharma A/S (ASND) · Health Care

Oppenheimer rates Ascendis Pharma A/S (ASND) Outperform with a $180 price target, as of its latest action on Sep 5, 2024. It has published 3 rating actions on ASND since February 2022, including 2 upgrades and 1 downgrade. Across 6 firms with a ASND price target in the last 12 months, the median target is $330.50.

Current rating

Outperform

Price target

$180

Median target, all firms

$330.50

Actions on ASND

3

Oppenheimer price target on ASND

Every Oppenheimer rating on ASND

• Sep 5, 2024
  UpgradeOppenheimer upgrades to Outperform from Perform, price target $180
• Apr 5, 2023
  DowngradeOppenheimer downgrades to Perform from Outperform
• Feb 14, 2022
  UpgradeOppenheimer upgrades to Outperform from Perform, price target $170

How other firms rate ASND

Each firm's latest rating and stated target in the last 12 months.

Questions about Oppenheimer and ASND

What is Oppenheimer's price target for ASND?

Oppenheimer's latest stated price target for Ascendis Pharma A/S (ASND) is $180, from its action on Sep 5, 2024.

What is Oppenheimer's rating on ASND?

Oppenheimer rates ASND Outperform, a bullish rating, as of Sep 5, 2024.

When did Oppenheimer last change its view on ASND?

On Sep 5, 2024, Oppenheimer upgrades to Outperform from Perform, price target $180.

How does Oppenheimer's ASND target compare with other analysts?

Across 6 firms with a ASND price target in the last 12 months, the median target is $330.50.

More ASND rating histories

• H.C. Wainwright3
• Morgan Stanley5
• Credit Suisse5

All Oppenheimer ratingsASND news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.